These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32407277)

  • 1. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [
    Xiao L; Xiang S; Chen C; Zhu H; Zhou M; Tang Y; Feng L; Hu S
    Psychiatry Clin Neurosci; 2024 Aug; 78(8):456-467. PubMed ID: 38804583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with levetiracetam reverses deficits in hippocampal LTP in vivo in experimental temporal lobe epilepsy rats.
    Ge YX; Tian XZ; Lin YY; Liu XY
    Neurosci Lett; 2016 Aug; 628():194-200. PubMed ID: 27345386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivaracetam Modulates Short-Term Synaptic Activity and Low-Frequency Spontaneous Brain Activity by Delaying Synaptic Vesicle Recycling in Two Distinct Rodent Models of Epileptic Seizures.
    Xing H; Han X; Xu S; Sun Z; Yang S
    J Mol Neurosci; 2022 May; 72(5):1058-1074. PubMed ID: 35278193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats.
    Detrait ER; Leclercq K; Löscher W; Potschka H; Niespodziany I; Hanon E; Kaminski RM; Matagne A; Lamberty Y
    Epilepsy Res; 2010 Sep; 91(1):74-83. PubMed ID: 20678901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.
    Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C
    Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
    Klein P; Bourikas D
    Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
    Okada M; Fukuyama K; Shiroyama T; Ueda Y
    Biomed Pharmacother; 2021 Jun; 138():111462. PubMed ID: 33706129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epileptic pilocarpine-treated rats exhibit aberrant hippocampal EPSP-spike potentiation but retain long-term potentiation.
    Carpenter-Hyland E; Bichler EK; Smith M; Sloviter RS; Benveniste M
    Physiol Rep; 2017 Nov; 5(21):. PubMed ID: 29138358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of TRPV1 on the hippocampal synaptic plasticity in the epileptic rat brain.
    Saffarzadeh F; Eslamizade MJ; Ghadiri T; Modarres Mousavi SM; Hadjighassem M; Gorji A
    Synapse; 2015 Jul; 69(7):375-83. PubMed ID: 25967571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
    Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
    Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.